{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:03:54Z","timestamp":1789956234209,"version":"4.0.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Martin-Luther-Universit\u00e4t Halle-Wittenberg","id":[{"id":"https:\/\/ror.org\/05gqaka33","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Aficamten is an approved drug to treat hypertrophic cardiomyopathy. Aficamten desensitizes bovine myofilaments against calcium cations. In isolated animal cardiac preparations, aficamten reduced force of contraction (FOC) but its effects on isolated human cardiac preparations has previously not been tested. Therefore, we studied the effects of aficamten on FOC in isolated electrically stimulated (1 Hz) human right atrial preparations (HAP) from adult patients that underwent cardiac surgery because they suffered from severe coronary heart disease. We detected a concentration-dependent negative inotropic effect of aficamten given alone in HAP. Likewise, aficamten reversed the positive inotropic effects of 1 \u00b5M isoprenaline or 10.8 mM calcium cations. 1 \u00b5M isoprenaline but not 10.8 mM calcium cations raised the phosphorylation state of phospholamban at serine 16 in HAP. Aficamten (10 \u00b5M) did not reduce the phosphorylation state of phospholamban at serine 16 in HAP that had been augmented by isoprenaline. Furthermore, aficamten reduced FOC that had been raised by stimulation of H\n                    <jats:sub>1<\/jats:sub>\n                    -histamine receptors, H\n                    <jats:sub>2<\/jats:sub>\n                    -histamine receptors, 5-HT\n                    <jats:sub>4<\/jats:sub>\n                    -serotonin receptors or D\n                    <jats:sub>1<\/jats:sub>\n                    -dopamine receptors in HAP. Moreover, aficamten diminished FOC that had been elevated by a calcium sensitizer (EMD57033), a serine\/threonine phosphatase inhibitor (100 \u00b5M cantharidin), 100 \u00b5M dibutyryl-cAMP, a membrane permeant 3\u00b4,5\u00b4-cyclic adenosine monophosphate (cAMP) derivative, or Bay K 8644, an activator of L-type calcium ion channels, in HAP. We conclude that aficamten diminished basal and elevated FOC in HAP, probably via reducing the calcium sensitivity of the human atrial myofilaments.\n                  <\/jats:p>","DOI":"10.1007\/s00210-026-05924-3","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T01:48:48Z","timestamp":1789955328000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Contractile effects of Aficamten in the human atrium"],"prefix":"10.1007","author":[{"given":"Joachim","family":"Neumann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Kirchhefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britt","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Gergs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"issue":"19","key":"5924_CR1","doi-asserted-by":"publisher","first-page":"14142","DOI":"10.1021\/acs.jmedchem.1c01290","volume":"64","author":"C Chuang","year":"2021","unstructured":"Chuang C, Collibee S, Ashcraft L, Wang W, Vander Wal M, Wang X, Hwee DT, Wu Y, Wang J, Chin ER, Cremin P, Zamora J, Hartman J, Schaletzky J, Wehri E, Robertson LA, Malik FI, Morgan BP (2021) Discovery of Aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy. J Med Chem 64(19):14142\u201314152. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01290","journal-title":"J Med Chem"},{"issue":"2","key":"5924_CR2","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1007\/s00210-024-03340-z","volume":"398","author":"U Gergs","year":"2025","unstructured":"Gergs U, Pham TH, Rayo Abella LM, Hesse C, Grundig P, Dhein S, Hofmann B, Neumann J (2025) Contractile effects of stimulation of D1-dopamine receptors in the isolated human atrium. Naunyn-Schmiedebergs Arch Pharmacol 398(2):1497\u20131508. https:\/\/doi.org\/10.1007\/s00210-024-03340-z","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"issue":"6","key":"5924_CR3","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1080\/00498254.2018.1495856","volume":"49","author":"MP Grillo","year":"2019","unstructured":"Grillo MP, Erve JCL, Dick R, Driscoll JP, Haste N, Markova S, Brun P, Carlson TJ, Evanchik M (2019) In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin. Xenobiotica 49(6):718\u2013733. https:\/\/doi.org\/10.1080\/00498254.2018.1495856","journal-title":"Xenobiotica"},{"issue":"8","key":"5924_CR4","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/s44161-024-00505-0","volume":"3","author":"JJ Hartman","year":"2024","unstructured":"Hartman JJ, Hwee DT, Robert-Paganin J, Chuang C, Chin ER, Edell S, Lee KH, Madhvani R, Paliwal P, Pernier J, Sarkar SS, Schaletzky J, Schauer K, Taheri KD, Wang J, Wehri E, Wu Y, Houdusse A, Morgan BP, Malik FI (2024) Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy. Nat Cardiovasc Res 3(8):1003\u20131016. https:\/\/doi.org\/10.1038\/s44161-024-00505-0","journal-title":"Nat Cardiovasc Res"},{"issue":"5870","key":"5924_CR5","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/298182a0","volume":"298","author":"EG Kranias","year":"1982","unstructured":"Kranias EG, Solaro RJ (1982) Phosphorylation of troponin I and phospholamban during catecholamine stimulation of rabbit heart. Nature 298(5870):182\u2013184. https:\/\/doi.org\/10.1038\/298182a0","journal-title":"Nature"},{"key":"5924_CR6","doi-asserted-by":"crossref","unstructured":"Lindemann JP, Watanabe AM (1985) Phosphorylation of phospholamban in intact myocardium. Role of Ca2+-calmodulin-dependent mechanisms. J Biol Chem 260(7):4516-25. PMID: 3156859","DOI":"10.1016\/S0021-9258(18)89294-8"},{"issue":"8","key":"5924_CR7","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jacbts.2022.04.008","volume":"7","author":"FI Malik","year":"2022","unstructured":"Malik FI, Robertson LA, Armas DR, Robbie EP, Osmukhina A, Xu D, Li H, Solomon SD (2022) A phase 1 dose-escalation study of the cardiac myosin inhibitor Aficamten in healthy participants. JACC Basic Transl Sci 7(8):763\u2013775. https:\/\/doi.org\/10.1016\/j.jacbts.2022.04.008","journal-title":"JACC Basic Transl Sci"},{"issue":"7","key":"5924_CR8","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","volume":"121","author":"AJ Marian","year":"2017","unstructured":"Marian AJ, Braunwald E (2017) Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res 121(7):749\u2013770. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.311059","journal-title":"Circ Res"},{"key":"5924_CR9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ijcard.2023.04.005","volume":"382","author":"D Massera","year":"2023","unstructured":"Massera D, Sherrid MV, Maron MS, Rowin EJ, Maron BJ (2023) How common is hypertrophic cardiomyopathy\u2026 really?: disease prevalence revisited 27 years after CARDIA. Int J Cardiol 382:64\u201367. https:\/\/doi.org\/10.1016\/j.ijcard.2023.04.005","journal-title":"Int J Cardiol"},{"key":"5924_CR10","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1097\/00005344-199505000-00015","volume":"25","author":"J Neumann","year":"1995","unstructured":"Neumann J, Boknik P, Schmitz W, Scholz H, Zimmermann N (1995a) Comparison of the stereoselective effects of a thiadiazinone derivative on contractile parameters and protein phosphorylation in the mammalian ventricle. J Cardiovasc Pharmacol 25:789\u2013793","journal-title":"J Cardiovasc Pharmacol"},{"key":"5924_CR11","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/S0022-3565(25)10676-9","volume":"274","author":"J Neumann","year":"1995","unstructured":"Neumann J, Herzig S, Boknik P, Apel M, Kaspareit G, Schmitz W, Scholz H, Zimmermann N (1995b) On the cardiac contractile, biochemical and electrophysiological effects of cantharidin, a phosphatase inhibitor. J Pharmacol Exp Ther 274:530\u2013539","journal-title":"J Pharmacol Exp Ther"},{"key":"5924_CR12","doi-asserted-by":"publisher","unstructured":"Neumann J, Grobe JM, Weisgut, J, Schwelberger HG, Fogel WA, Wache H, B\u00e4hre H, Buchwalow IB, Dhein S, Hofmann B, Kirchhefer U, Gergs U (2021) Histamine can be formed and degraded in the human and mouse heart. Front Pharmacol 12:582916.\u00a0https:\/\/doi.org\/10.3389\/fphar.2021.582916","DOI":"10.3389\/fphar.2021.582916"},{"key":"5924_CR13","doi-asserted-by":"publisher","unstructured":"Neumann J, Hofmann B, Gergs U (2026) On indirect negative inotropic effects of muscarine in the isolated human atrium. Naunyn-Schmiedeberg\u00b4s Arch Pharmacol https:\/\/doi.org\/10.1007\/s00210-026-05666-2 Online ahead of print","DOI":"10.1007\/s00210-026-05666-2"},{"issue":"6","key":"5924_CR14","doi-asserted-by":"publisher","first-page":"7235","DOI":"10.1007\/s00210-024-03735-y","volume":"398","author":"TH Pham","year":"2024","unstructured":"Pham TH, Rayo Abella LM, Hadova K, Klimas J, Dhein S, Pockes S, Schlicht JMA, Hofmann B, Kirchhefer U, Neumann J, Gergs U (2024) Stimulation of histamine H1-receptors produces a positive inotropic effect in the human atrium. Naunyn-Schmiedebergs Arch Pharmacol 398(6):7235\u20137250. https:\/\/doi.org\/10.1007\/s00210-024-03735-y","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"5924_CR15","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s00210-022-02333-0","volume":"396","author":"LM RayoAbella","year":"2023","unstructured":"RayoAbella LM, H\u00f6hm C, Hofmann B, Gergs U, Neumann J (2023a) Effects of omecamtiv mecarbil and mavacamten in isolated human atrium. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 396:499\u2013511. https:\/\/doi.org\/10.1007\/s00210-022-02333-0","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"5924_CR16","doi-asserted-by":"publisher","unstructured":"Rayo Abella LM, Grundig P, Bernhardt MN, Hofmann B, Neumann J, Gergs U (2023b) OR-1896 increases the force of contraction in the isolated human atrium. Naunyn-Schmiedeberg\u00b4s Arch Pharmacol 396(12):3823\u20133833. Online ahead of print. https:\/\/doi.org\/10.1007\/s00210-023-02592-5","DOI":"10.1007\/s00210-023-02592-5"},{"key":"5924_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-026-01194-5","author":"F S\u00e1rk\u00e1ny","year":"2026","unstructured":"S\u00e1rk\u00e1ny F, Priksz D, Juh\u00e1sz B, Fazekas L\u00c1, N\u00e9meth N, Szentandr\u00e1ssy N, Horv\u00e1th B, Kov\u00e1cs ZM, Borb\u00e9ly A, R\u00e1duly AP, T\u00f3th A, Fagyas M, B\u00f3di B, Papp Z (2026) Myofilament-level effects of aficamten increase diastolic chamber volumes and maintain cardiac output through preserved length-dependent force generation in healthy rat and canine myocardium. Basic Res Cardiol. https:\/\/doi.org\/10.1007\/s00395-026-01194-5","journal-title":"Basic Res Cardiol"},{"issue":"10","key":"5924_CR18","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1007\/s00210-023-02483-9","volume":"396","author":"R Schwarz","year":"2023","unstructured":"Schwarz R, Hofmann B, Gergs U, Neumann J (2023) Cantharidin increases the force of contraction and protein phosphorylation in the isolated human atrium. Naunyn- Schmiedeberg\u2019s Arch Pharmacol 396(10):2613\u20132625. https:\/\/doi.org\/10.1007\/s00210-023-02483-9","journal-title":"Naunyn- Schmiedeberg\u2019s Arch Pharmacol"},{"issue":"7","key":"5924_CR19","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3390\/cimb48070698","volume":"48","author":"R Schwarz","year":"2026","unstructured":"Schwarz R, Hofmann B, Gergs U, Kirchhefer U, Neumann J (2026) Phosphatase inhibition attenuates the negative inotropic effect of muscarinic receptors in the presence of serotonin. Curr Issues Mol Biol 48(7):698. https:\/\/doi.org\/10.3390\/cimb48070698","journal-title":"Curr Issues Mol Biol"},{"key":"5924_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-026-02307-z","author":"M Shirley","year":"2026","unstructured":"Shirley M (2026) Aficamten: first approval. Drugs. https:\/\/doi.org\/10.1007\/s40265-026-02307-z","journal-title":"Drugs"},{"issue":"4","key":"5924_CR21","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1152\/physrev.1998.78.4.921","volume":"78","author":"HK Simmerman","year":"1998","unstructured":"Simmerman HK, Jones LR (1998) Phospholamban: protein structure, mechanism of action, and role in cardiac function. Physiol Rev 78(4):921\u2013947. https:\/\/doi.org\/10.1152\/physrev.1998.78.4.921","journal-title":"Physiol Rev"},{"issue":"1","key":"5924_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1476-5381.1996.tb15675.x","volume":"119","author":"G Sitzler","year":"1996","unstructured":"Sitzler G, Lenz O, Kilter H, La Rosee K, B\u00f6hm M (1996) Investigation of the negative inotropic effects of 17 beta-oestradiol in human isolated myocardial tissues. Br J Pharmacol 119(1):43\u201348. https:\/\/doi.org\/10.1111\/j.1476-5381.1996.tb15675.x","journal-title":"Br J Pharmacol"},{"issue":"5","key":"5924_CR23","doi-asserted-by":"publisher","first-page":"e70006","DOI":"10.1002\/prp2.70006","volume":"12","author":"D Xu","year":"2024","unstructured":"Xu D, Divanji P, Griffith A, Sukhun R, Cheplo K, Li J, German P (2024) Pharmacokinetics, disposition, and biotransformation of the cardiac myosin inhibitor aficamten in humans. Pharmacol Res Perspect 12(5):e70006. https:\/\/doi.org\/10.1002\/prp2.70006","journal-title":"Pharmacol Res Perspect"},{"issue":"3","key":"5924_CR24","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40262-025-01481-9","volume":"64","author":"D Xu","year":"2025","unstructured":"Xu D, Lutz JD, Divanji P, Li J, Benattia Y, Griffith A, Heitner SB, Kupfer S, German P (2025) Effect of hepatic impairment or renal impairment on the pharmacokinetics of aficamten. Clin Pharmacokinet 64(3):397\u2013406. https:\/\/doi.org\/10.1007\/s40262-025-01481-9","journal-title":"Clin Pharmacokinet"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05924-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05924-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05924-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T01:48:50Z","timestamp":1789955330000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05924-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":24,"alternative-id":["5924"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05924-3","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"27 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Humans:\n                      This study in patients complies with the Declaration of Helsinki and has been approved by the local ethics committee (internal code: hm-b\u00fc).","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed written consent was obtained from all patients included in the study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have seen and approved the submitted version of this manuscript.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no competing financial, nonfinancial, or personal interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Does not apply.","order":5,"name":"Ethics","label":"Clinical trials number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}